AstraZeneca effective against Delta, Kappa COVID variants: Oxford study

AstraZeneca’s COVID-19 vaccine is effective against Delta and Kalpa variants of coronavirus, the pharmaceutical company said citing a study on Tuesday. First identified in India, Delta and Kappa variants of novel coronavirus have triggered fresh safety concerns around the globe. 

The study, conducted by the Oxford University, investigated the ability of monoclonal antibodies in blood from COVID-recovered people and from vaccinated people to neutralise the Delta and Kappa variants, Reuters reported. 

Also Read | Angela Merkel, 1st leader to get mixed COVID vaccine doses

This comes after an analysis by the Public Health England (PHE) showed that Pfizer and AstraZeneca vaccines offer protection of over 90% against hospitalisation from the Delta variant of the virus. 

The World Health of Organization’s chief scientist recently said that the Delta variant has become the global domination version of COVID-19. 

Also Read | AstraZeneca vaccine linked to rare neurological disorder in India, UK

US’s top infectious disease expert, Anthony Fauci recently said that the Delta variant is more transmissible and is associated with the increased risk of hospitalisation as compared to the Alpha variant of coronavirus.